Deals, Partnering

Nuron Biotech licenses HibTITER vaccine to Mitsubishi Tanabe for Japanese market

Posted on 16 January 2012

Tags: , , ,

Nuron Biotech has licensed its HibTITER vaccine to Mitsubishi Tanabe Pharma for commercialization in the Japanese market for both the single entity and for combination product use. 

Under the terms of the agreement MTPC will be responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron Biotech significant royalties on commercial sales in Japan.

“The HibTITER® vaccine still represents a considerable global opportunity, especially in markets like Japan, where there is only one approved vaccine for Haemophilus influenza type b (Hib) bacteria, which is a potential life-threatening illness,” commented Shankar Musunuri, Ph.D., MBA, Chief Executive Officer and Founder of Nuron Biotech. “This agreement provides us with additional resources to accelerate our re-launch strategy of this first-in-class vaccine in the U.S. market.”

“HibTITER®’s easy to use liquid formulation, adjuvant free, with a track record of success in virtually eliminating Haemophilus in the United States makes it a great addition to our pediatric vaccine franchise,” said Masayuki Mitsuka, Ph.D., Board Director, Executive Officer, Global Product Strategy at MTPC.

Richard Dinovitz, Vice President, Marketing and Business Development at Nuron Biotech continued, “MTPC is one of Japan’s largest and most respected pharmaceutical companies, and we believe they have both the experience and market access to bring HibTITER® to patients and clinicians across Japan.”


Purchase the on-demand report Partnering Agreements with Mitsubishi Tanabe

See more deal data at Current Agreements (subscription required)

Print Friendly, PDF & Email

Leave a Reply